Black­stone throws $250M be­hind In­tel­lia-Cellex quest to com­bine CRISPR and con­trol­lable CAR-Ts

So here’s how Black­stone is spend­ing its $4.6 bil­lion bio­phar­ma pot.

The pri­vate eq­ui­ty firm an­nounced Tues­day they were team­ing with the CRISPR biotech In­tel­lia and the lit­tle-known Ger­man CAR-T start­up GEMoaB to launch a new — and so far un­named — CAR-T com­pa­ny. Black­stone, the sole in­vestor, will pour $250 mil­lion in­to the joint ven­ture and take a third own­er­ship. In­tel­lia and Cellex, GEMoaB’s par­ent com­pa­ny, will each take an­oth­er third.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER